Vericel (VCEL) Accumulated Expenses (2010 - 2026)
Vericel recorded quarterly Accumulated Expenses of $14.0 million in Q1 2026, down 27.39% quarter-over-quarter from $19.2 million in Q4 2025, and up 22.32% year-over-year from $11.4 million in Q1 2025.
Vericel's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $14.0 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 22.32% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (up 22.32% YoY), while the FY2025 annual figure was $19.2 million, up 12.72% from the prior year.
- Accumulated Expenses came in at $14.0 million for Q1 2026 at Vericel, down from $19.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $19.2 million in Q4 2025 to a low of $10.8 million in Q1 2022.
- A 5-year average of $14.2 million and a median of $14.0 million in 2026 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses gained 27.59% in 2022 and dropped 15.9% in 2024, its largest moves.
- Vericel's Accumulated Expenses stood at $16.2 million in 2022, then increased by 6.33% to $17.2 million in 2023, then dropped by 0.87% to $17.1 million in 2024, then rose by 12.72% to $19.2 million in 2025, then decreased by 27.39% to $14.0 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $14.0 million, $19.2 million, and $16.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.97 Mn |
| Dec 31, 2025 | 19.24 Mn |
| Sep 30, 2025 | 16.29 Mn |
| Jun 30, 2025 | 14.40 Mn |
| Mar 31, 2025 | 11.42 Mn |
| Dec 31, 2024 | 17.07 Mn |
| Sep 30, 2024 | 14.34 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Mar 31, 2024 | 11.03 Mn |
| Dec 31, 2023 | 17.22 Mn |
| Sep 30, 2023 | 13.63 Mn |
| Jun 30, 2023 | 13.97 Mn |
| Mar 31, 2023 | 13.11 Mn |
| Dec 31, 2022 | 16.19 Mn |
| Sep 30, 2022 | 13.95 Mn |
| Jun 30, 2022 | 12.13 Mn |
| Mar 31, 2022 | 10.79 Mn |
| Dec 31, 2021 | 14.05 Mn |
| Sep 30, 2021 | 10.93 Mn |
| Jun 30, 2021 | 11.08 Mn |
| Mar 31, 2021 | 9.97 Mn |
| Dec 31, 2020 | 11.29 Mn |
| Sep 30, 2020 | 8.70 Mn |
| Jun 30, 2020 | 7.98 Mn |
| Mar 31, 2020 | 6.15 Mn |
| Dec 31, 2019 | 7.95 Mn |
| Dec 31, 2018 | 6.93 Mn |
| Mar 31, 2018 | 678,000.00 |
| Dec 31, 2017 | 5.57 Mn |
| Sep 30, 2017 | 379,000.00 |
| Jun 30, 2017 | 589,000.00 |
| Mar 31, 2017 | 605,000.00 |
| Dec 31, 2016 | 4.52 Mn |
| Sep 30, 2016 | 24,000.00 |
| Jun 30, 2016 | 82,000.00 |
| Mar 31, 2016 | 16,000.00 |
| Dec 31, 2015 | 3.60 Mn |
| Sep 30, 2015 | 85,000.00 |
| Jun 30, 2015 | 140,000.00 |
| Mar 31, 2015 | 154,000.00 |
| Dec 31, 2014 | 4.71 Mn |
| Sep 30, 2014 | 2.18 Mn |
| Jun 30, 2014 | 2.51 Mn |
| Mar 31, 2014 | 406,000.00 |
| Dec 31, 2013 | 620,000.00 |
| Sep 30, 2013 | 299,000.00 |
| Jun 30, 2013 | 458,000.00 |
| Mar 31, 2013 | 858,000.00 |
| Dec 31, 2012 | 383,000.00 |
| Sep 30, 2012 | 742,000.00 |
| Jun 30, 2012 | 945,000.00 |
| Mar 31, 2012 | 1.40 Mn |
| Dec 31, 2011 | 724,000.00 |
| Sep 30, 2011 | 1.01 Mn |
| Jun 30, 2011 | 688,000.00 |
| Dec 31, 2010 | 796,000.00 |